ABT Stock Recent News

Abbott Laboratories CEO Robert Ford unpacked his company's latest quarterly report in a Thursday interview with CNBC's Jim Cramer, saying that Wall Street's reaction to the results was too extreme. "I think this is a little bit of an overreaction.

Live Updates Live Coverage Has Ended Abbott Still Down 8% 2:38 pm by Eric Bleeker We’re approaching the end of the trading day and Abbott remains down 8%. At the end of the day, the company narrowing forward guidance appears to be Wall Street’s focus. After earnings Abbott trades for a P/E of about 15.6X, which is attractive for a company with its current earnings growth. Abbott Continues to Sink 12:03 pm by Eric Bleeker As of midday, shares of Abbott continue to trend lower. The company’s shares are down about 8%. While Abbott’s shares have plummeted today, they are still up about 7% year-to-date. Growth Rates 10:50 am by Eric Bleeker Here’s a look at Abbott’s growth rates: Metric Q2 25 Q2 2024 YoY Change revenue $11.14B $10.38B 7.37% gross profit $5.87B $5.81B 1.05% operating income $2.05B $1.72B 19.09% net income $1.78B $1.30B 36.64% While shares are down today, the company is posting impressive for a stock now trading at 16X earnings. Q&A Tak

Abbott Laboratories (NYSE:ABT ) Q2 2025 Results Conference Call July 17, 2025 9:00 AM ET Company Participants Michael Comilla - Vice President of Investor Relations. Philip P. Boudreau - CFO & Executive VP of Finance Robert B.

Abbott Laboratories (ABT -8.41%), a global healthcare company known for its medical devices, diagnostics, nutrition, and pharmaceuticals, reported fiscal 2025 earnings on Thursday, July 17, that narrowly topped analysts' consensus estimates. Q2 revenue climbed to $11.14 billion, surpassing the analyst estimate of $11.06 billion, and adjusted earnings per share came in at $1.26, beating the consensus by $0.01.

ABT beats on Q2 earnings and revenues with double-digit growth in Medical Devices, yet shares fall 5% pre-market.

Jaguar Land Rover is cutting up to 500 management jobs in the UK following a sharp drop in global sales and trade disruption with the US. The voluntary redundancy programme affects around 1.5% of the carmaker’s UK workforce and is targeted at managerial roles, the company confirmed. The move follows a 15.1% drop in retail sales for the three months to June, driven by a pause in exports to the US and the planned phase-out of older Jaguar models. JLR halted US shipments in April after the American government threatened a 25% tariff on imported vehicles. A deal later reduced this to 10% on the first 100,000 UK cars, but volumes beyond that threshold will still face a 27.5% levy. North American sales fell 12.2% year-on-year, while UK sales plunged 25.5%. JLR has paused domestic sales as it transitions to new electric models due to launch in 2026. American Resources Corp (NASDAQ:AREC) and its affiliate ReElement Technologies on Wednesday signaled strong support for the newly announced Qua

Abbott Laboratories (NYSE:ABT) shares moved more than 6% lower as disappointing guidance overshadowed solid second quarter results.  The company now expects full-year earnings per share (EPS) in the range of $5.10 to $5.20, which reflects double-digit growth at the midpoint, tightening from earlier guidance of $5.05 to $5.25.

Although the revenue and EPS for Abbott (ABT) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Abbott (ABT) came out with quarterly earnings of $1.26 per share, beating the Zacks Consensus Estimate of $1.25 per share. This compares to earnings of $1.14 per share a year ago.

U.S. stock futures were mostly lower this morning, with the Dow futures falling around 0.2% on Thursday.